17-Alpha Hydroxyprogesterone (Neonatal Screening) test in Dubai and across the UAE to detect congenital adrenal hyperplasia (CAH) in newborns. This life-saving screening helps identify babies at risk of hormonal imbalances, adrenal crisis, or genital abnormalities. Results available within 5–10 days.

Overview

The 17-Alpha Hydroxyprogesterone (17-OHP) Neonatal Screening test is a critical part of newborn screening programs in the UAE. It measures 17-OHP levels in a dried blood spot to detect 21-hydroxylase deficiency — the most common form of congenital adrenal hyperplasia (CAH). Early detection allows immediate treatment to prevent life-threatening adrenal crises, electrolyte imbalances, and developmental issues. Results are typically available within 5–10 days.

Why You Need This Test

• Early detection of congenital adrenal hyperplasia (CAH) before symptoms appear.
• Prevent adrenal crisis (vomiting, dehydration, shock) in newborns with salt-wasting CAH.
• Identify babies at risk of ambiguous genitalia (especially in genetic females).
• Mandatory screening in many UAE hospitals between day 2 and day 5 of life.
• Support early intervention with hormone replacement and monitoring.
• Part of a comprehensive newborn metabolic screening panel.
• Available for home follow-up testing if initial screening was delayed.

Symptoms & Risk Factors

Common Signs (if untreated)

• Poor feeding, vomiting, or weight loss in the first week of life.
• Dehydration, low sodium, high potassium — signs of salt-wasting crisis.
• Darkened skin (hyperpigmentation) due to high ACTH.
• Genital abnormalities in genetic females (enlarged clitoris, fused labia).
• Low blood sugar or lethargy.

Risk Factors

• Family history of congenital adrenal hyperplasia (CAH).
• Consanguineous parents (increased genetic risk).
• Previous child diagnosed with CAH in the family.
• Not screened at birth — late or missed newborn screening.
• Preterm infants: may have transiently elevated 17-OHP (requires follow-up).

How the Test Works

The test measures 17-alpha-hydroxyprogesterone (17-OHP) — a hormone that builds up when the adrenal gland can't make cortisol due to enzyme deficiency.

• Step 1 — Timing: ideally performed between the 2nd and 5th day of life (after full feeding).
• Step 2 — Sample collection: a small blood sample is taken via heel prick and blotted onto a filter paper card (dried blood spot).
• Step 3 — Documentation: a complete Clinical History form must accompany the sample, including birth date, birth time, feeding status, and gestational age.
• Step 4 — Lab analysis: specialized immunoassay measures 17-OHP levels.
• Step 5 — Results: delivered securely within 5–10 business days.

This non-invasive test is a cornerstone of preventive pediatric care in the UAE.

Specimen (Sample Type)

• Required sample: Dried Blood Spot (DBS) from heel prick
• Collection window: ideally between Day 2 and Day 5 of life
• Form required: completed Clinical History form (birth date, birth time, feeding, gestational age)
• Handling: avoid touching or smearing the blood spots — use clean hands and proper technique
• Drying: air-dry horizontally for a minimum of 3 hours
• Transport: ship to the lab as soon as dry, and no later than 24 hours after collection
• Note: improperly handled or delayed specimens may be rejected

Risks & Safety

• Minimal discomfort: brief pinch during heel prick.
• Small bruise or redness at the site — resolves quickly.
• No infection risk when sterile lancets are used.
• No long-term risks — this is a standard, safe screening procedure.

Result Interpretation

Normal Range

• Term infants: usually < 200 ng/dL (lab-dependent cutoff)
• Levels vary by age, birth weight, and time of collection

Elevated Levels

• May indicate:
  • Classic 21-hydroxylase deficiency (CAH)
  • Non-classic CAH (milder form)
  • Preterm birth (transient elevation)
  • Stress or illness in newborn period
• Abnormal screen requires urgent follow-up with serum 17-OHP, cortisol, and electrolytes.

False Positives

• More common in preterm, low birth weight, or sick infants.
• Requires repeat testing to confirm.

Consequences if Untreated

• Adrenal crisis: vomiting, dehydration, shock, death within days.
• Electrolyte imbalance: low sodium, high potassium, cardiac arrhythmias.
• Permanent genital abnormalities in undiagnosed genetic females.
• Delayed diagnosis increases risk of hospitalization and long-term complications.

Factors Affecting Test Results

• Timing: testing too early (<24h) or too late (>5 days) reduces accuracy.
• Birth weight: preterm infants often have higher 17-OHP.
• Feeding status: must be fed before testing — affects hormone levels.
• Stress or illness: can elevate 17-OHP temporarily.
• Sample handling: touching, smearing, or delayed transport affects reliability.

FAQs

Limitations

• Not 100% diagnostic — elevated results require confirmatory serum testing.
• May miss non-classic or late-onset CAH (use serum test for older children).
• Higher false positive rate in preterm or ill newborns.
• Strict collection and transport rules — improper handling leads to sample rejection.
• Must be collected within the 2nd–5th day window for optimal accuracy.

Book Your 17-Alpha Hydroxyprogesterone (Neonatal Screening) Test Today

Protect your baby’s health from day one — early detection saves lives.

• Home Neonatal Screening Available (Across Abu Dhabi, Dubai, Sharjah, Ajman, RAK, Umm Al Quwain, Fujairah)
• Fast, Accurate, Confidential Results in 5–10 Days
• Price: AED 150
• ✅ Certified Labs | Newborn Screening Accredited
• 👶 Trained Pediatric Nurses for Home Collection
• 🔒 Secure Reporting & Doctor Support

The Alpha Feto Protein (AFP) test is a prenatal screening that measures various health markers in the serum. This test is recommended for pregnant individuals between 14 to 22 weeks of gestation to assess the risk of certain fetal conditions.

The Anti Ovary Antibodies test measures various health markers related to ovarian function and autoimmune disorders. This test is essential for diagnosing conditions that may affect fertility and hormonal balance. Accurate results can guide treatment options for individuals facing reproductive challenges.

The Anti Sperm Antibody Test measures the presence of antibodies that may affect sperm function and fertility. This test is essential for evaluating male infertility and understanding potential immunological factors impacting reproductive health.

The Anti-Sperm Antibodies test measures the presence of antibodies that may affect sperm function and fertility. This test is crucial for evaluating male infertility and understanding potential immune responses against sperm. Various health markers are assessed to provide insights into reproductive health.

The C/S, Aerobic, Semen test is a laboratory analysis that evaluates the presence of bacteria and other microorganisms in semen. This test is crucial for diagnosing infections that may affect male fertility or lead to other reproductive health issues.

The C/S, Aerobic, Semen test analyzes various health markers in semen to assess male reproductive health. This test can help identify infections or abnormalities that may affect fertility and overall health.

The Cancer Antigen (CA 125) test measures the levels of CA 125 protein in the blood, which can be an indicator of ovarian cancer and other conditions. This test helps in monitoring treatment response and detecting recurrence in patients with a history of ovarian cancer.

The Free Beta HCG level test measures various health markers related to pregnancy and certain medical conditions. This test is essential for monitoring hormone levels that can indicate pregnancy status or other health issues.

The Free Beta HCG test measures various health markers related to pregnancy and certain medical conditions. It is crucial for monitoring hCG levels in the body, which can indicate pregnancy status or other health issues.

Tests for presence of fructose in semen.

Inhibin B is a crucial test that measures various health markers related to reproductive health. It plays a significant role in assessing ovarian function and can help in the diagnosis and monitoring of certain conditions.

NIPT - Basic (NON-CE IVD) | Test for Trisomy 21, 18, 13, Sex Chromosome Abnormalities & Gender

The Non-Invasive Prenatal Test (NIPT) - Basic (NON-CE IVD) screens for common chromosomal abnormalities including:

• - Trisomy 21 (Down Syndrome)
• - Trisomy 18
• - Trisomy 13
• - Sex chromosome abnormalities
• - Fetal gender determination

This test uses just 10 mL of maternal blood, collected in a special tube provided by Lifenity. It is valid from 10 weeks of gestation onwards.

Why You Need This Test

NIPT is an essential screening for expecting parents seeking peace of mind about their baby’s health. It is:

• - Non-invasive and safe for both mother and baby
• - Highly accurate for detecting genetic disorders
• - Performed early in pregnancy (from 10 weeks)
• - A powerful alternative to riskier invasive tests like amniocentesis

Symptoms or Risk Factors That Indicate the Need for This Test

• - Mother’s age is 35 years or older
• - Abnormal findings on a prenatal ultrasound
• - Family history of genetic or chromosomal disorders
• - Positive results from first-trimester screenings
• - Previous pregnancy affected by chromosomal conditions

Understanding Natural Fetal Chromosome Development

Most pregnancies result in a typical number of chromosomes, but errors can occur during fetal development. These errors may lead to conditions such as:

• - Down Syndrome (Trisomy 21)
• - Edwards Syndrome (Trisomy 18)
• - Patau Syndrome (Trisomy 13)
• - Sex chromosome abnormalities like Turner or Klinefelter syndrome

NIPT analyzes fetal DNA from the mother's blood, providing early detection with high accuracy and no risk to the fetus.

What Happens If It Goes Undiagnosed?

• - Potential emotional and medical distress later in pregnancy
• - Lack of preparedness for medical care or interventions at birth
• - Increased difficulty in making informed decisions
• - Delayed access to genetic counseling or supportive care

Early screening allows timely action and better prenatal care planning.

Detects hCG in urine to confirm pregnancy.

A Semen Analysis with Morphology is a critical diagnostic test that evaluates the quality and characteristics of a man's sperm. This test measures various parameters, including sperm count, motility, and morphology, to assess male fertility and identify potential reproductive issues.

Semen analysis with morphology is a comprehensive test that evaluates various health markers in a semen sample. This test assesses sperm count, motility, morphology, and other critical parameters to provide insights into male reproductive health.

A Semen Analysis with Semen Fructose test evaluates the quality and quantity of sperm in a semen sample, along with measuring the fructose levels, which can indicate the functionality of the seminal vesicles. This test is essential for diagnosing male infertility and assessing reproductive health.

Semen analysis with semen fructose is a comprehensive test that evaluates various health markers in a semen sample. This test helps assess male fertility and can provide insights into potential reproductive issues.

The Semen Fructose test measures the level of fructose present in a semen sample, which is an important indicator of seminal vesicle function. This test is often used to evaluate male fertility and diagnose potential reproductive issues.

The Semen Fructose test measures the level of fructose in semen, which can provide insights into male reproductive health. It is essential for evaluating various health markers related to fertility and seminal fluid quality.

The Sickling Test is a diagnostic procedure used to identify the presence of sickle-shaped red blood cells in a blood sample, which can indicate sickle cell disease or trait. This test is crucial for early detection and management of hemoglobinopathies, allowing for timely intervention and treatment.

The Sperm Antibody Test evaluates the presence of antibodies that may affect sperm function and fertility. This test measures various health markers that can indicate potential reproductive issues. It is essential for individuals experiencing infertility or related concerns.

The Triple Marker Test is a crucial prenatal screening that measures various health markers to assess the risk of certain genetic conditions in the fetus. This test provides valuable information that can guide further diagnostic testing and management during pregnancy.